CD40 ligation reverses T cell tolerance in acute myeloid leukemia

Long Zhang, Xiufen Chen, Xiao Liu, Douglas E. Kline, Ryan M. Teague, Thomas F. Gajewski, and Justin Kline

Introduction

Although it is widely accepted that cancer cells can express antigens that are recognizable to host T cells (1), spontaneous immune-mediated elimination of established malignancies is rare. This is believed to be due in large part to immune evasion pathways active within the tumor microenvironment that subvert the generation or execution of an effective antitumor immune response (2). Analysis of the major immune evasion pathways has predominantly focused on solid tumor models, either preclinically or in clinical specimens. Such investigations have been profitable, as strategies to overcome these immune-inhibitory pathways are meeting with early clinical success. For example, immune checkpoint blockade is rapidly emerging as an effective strategy to enhance antitumor immunity in patients with melanoma and several other solid malignancies. In particular, phase II and III studies of anti–CTLA-4 and anti–PD-L1 Abs have demonstrated impressive objective tumor response rates (3, 4), and administration of the anti–CTLA-4 Ab ipilimumab (Yervoy; Bristol-Myers Squibb) has been shown to prolong survival in patients with advanced melanoma (3). In addition, early-phase clinical trials are underway to test strategies to deplete CD4+CD25+FoxP3+ Tregs (5); to block the enzymatic activity of indoleamine-2,3-dioxygenase (IDO); and to reverse tumor-induced T cell anergy through T cell homeostatic proliferation, OX40 ligation, and LAG-3 blockade (6, 7). Each of these interventions has been supported by preclinical studies in solid tumor models (8–11), or execution of an effective antitumor immune response (2). Analysis of the major immune evasion pathways has predominantly focused on solid tumor models, either preclinically or in clinical specimens. Such investigations have been profitable, as strategies to overcome these immune-inhibitory pathways are meeting with early clinical success. For example, immune checkpoint blockade is rapidly emerging as an effective strategy to enhance antitumor immunity in patients with melanoma and several other solid malignancies. In particular, phase II and III studies of anti–CTLA-4 and anti–PD-L1 Abs have demonstrated impressive objective tumor response rates (3, 4), and administration of the anti–CTLA-4 Ab ipilimumab (Yervoy; Bristol-Myers Squibb) has been shown to prolong survival in patients with advanced melanoma (3). In addition, early-phase clinical trials are underway to test strategies to deplete CD4+CD25+FoxP3+ Tregs (5); to block the enzymatic activity of indoleamine-2,3-dioxygenase (IDO); and to reverse tumor-induced T cell anergy through T cell homeostatic proliferation, OX40 ligation, and LAG-3 blockade (6, 7). Each of these interventions has been supported by preclinical studies in solid tumor models (8–11), often induced through s.c. tumor cell inoculation.

In contrast to the translational research progress being made uncoupling immune inhibitory mechanisms in the setting of solid tumors, the negative regulatory mechanisms orchestrated by hematologic malignancies, such as acute myeloid leukemia (AML), have been underexplored. However, several groups have investigated T cell tolerance in systemic hematological cancer models. The first observation of T cell tolerance to a systemic hematological malignancy was demonstrated in the transplantable A20 lymphoma model. TCR-Tg CD4+ T cells specific for a model tumor antigen were rendered “anergic” in tumor-bearing mice (12). The CD4+ T cell tolerance was regulated by host APCs (13) and could not be prevented with CTLA-4 blockade and vaccination (14). Furthermore, in a model of CD8+ T cell tolerance in hosts harboring Friend murine leukemia virus–transformed leukemia (FBL), which expresses an immunogenic peptide derived from the retroviral Gag protein, it was observed that Gag-specific CD8+ T cells were tolerized in FBL-bearing hosts in which the Gag antigen was also conditionally expressed in the liver. This antigen-specific CD8+ T cell tolerant state could not be prevented by administration of agonistic anti-CD40 Ab or LPS, but was reversible after in vivo administration of IL-15 (15).

Because hematological malignancies differ greatly in their growth rate and pattern and stromal milieu compared with tumors that progress locally as a solid mass, it seemed likely that their interactions with the host immune system might be distinct. Recent observations from solid tumor models have suggested that local inflammation generated by tumor cell death can result in the elaboration of “danger signals” that activate host innate immune cells (16, 17), including CD8+ DCs (18). Activated DCs can consequently cross-present tumor-derived antigens and initiate CD8+ T cell activation, resulting in a spontaneous antitumor T cell response. However, in the case of disseminated leukemia, it is conceivable that this immunogenic cell death might not occur to a similar degree. Therefore, the nature of the major immune evasion mechanisms active in hosts with leukemia also might be distinct. Understanding these mecha-
nisms should point toward the most logical immunotherapeutic strategies for patients with hematologic malignancies. With these notions in mind, we used a transplantable model of AML in which leukemia cells were introduced i.v. or s.c. into mice in order to analyze both spontaneous immune responses and mechanisms of immune escape. After i.v. inoculation, AML cells infiltrated the liver and, to a lesser extent, the bone marrow and peripheral blood of recipient mice (19, 20). Interestingly, it was observed that i.v. inoculation of AML cells prevented the generation of an antigen-specific T cell response induced by s.c. inoculation in the same mouse, indicating a rapid induction of peripheral tolerance. This tolerance appeared to be due to the intrinsic dysfunction and deletion of antitumor T cells, and was reversed by administration of an agonistic anti-CD40 Ab that has been previously demonstrated to overcome peripheral T cell tolerance in several preclinical solid tumor models (21–23). Our findings suggest that dominant peripheral tolerance is a major mechanism of immune escape with hematogenous dissemination of leukemia and that anti-CD40 mAb may have a therapeutic benefit that could be translated clinically.

Results

Diminished survival in C57BL/6 mice after i.v. versus s.c. challenge with C1498 AML. To begin to investigate the role of adaptive immunity in the control of AML progression, we challenged cohorts of C57BL/6 and T cell/B cell–deficient Rag2–/– hosts i.v. or s.c. with 10⁶ C1498.SIY cells (engineered by retroviral transduction using the pLEGFP plasmid expressing cDNA for the SIYRYYGL model peptide antigen; see Methods), and survival was assessed. Whereas no difference in survival was seen after inoculation of C1498.SIY cells i.v. versus s.c. in Rag2–/– hosts, C57BL/6 mice challenged with s.c. C1498.SIY cells demonstrated significantly prolonged survival compared with i.v. inoculation, and approximately 20% of mice survived long-term (Figure 1A). These results suggested that a partial adaptive immune response was generated when C1498 cells were implanted s.c., but not i.v. Furthermore, the similar survival we observed in C1498.SIY cell–challenged Rag2–/– mice (unable to mount an adaptive immune response against C1498.SIY cells), regardless of inoculation route, argued that the “antigen” load to which mice were exposed was similar when comparing s.c. and i.v. routes of inoculation.

Minimal functional antigen-specific T cell responses are generated in mice harboring C1498.SIY cells i.v. To test directly whether antigen-specific T cell responses were occurring in C57BL/6 mice after i.v. versus s.c. C1498 cell inoculation, spleens and LNs were harvested from groups of C57BL/6 mice at various time points after either i.v. or s.c. C1498.SIY cell inoculation, and the number and function of SIY-reactive CD8+ T cells were analyzed using SIY/Kb tetramers and IFN-γ ELISPOT. SIY pentamer–reactive CD8+ T cells were more numerous in the spleens of C57BL/6 mice challenged with C1498.SIY cells s.c. versus i.v. on day 10 after C1498.SIY cell challenge (Figure 1B and C). Furthermore, when the function of SIY-specific T cells was analyzed with IFN-γ ELISPOT, significantly higher numbers of IFN-γ spot-forming cells were observed in mice 5 and 10 days after s.c. C1498.SIY cell challenge (Figure 1D). In contrast, in C57BL/6 mice challenged with C1498.SIY cells i.v., only minimal functional responses were detected at all time points analyzed. A similar, although slightly delayed, kinetic pattern of functional activation of endogenous C1498–specific T cells was seen in mice challenged with control C1498.GFP cells (Figure 1E), which indicates that the impaired priming or activation of tumor antigen-specific T cells in hosts harboring leukemia cells systemically was not limited to T cells specific for the model SIY antigen.

Generation of antigen-specific T cell dysfunction after i.v. C1498.SIY cell inoculation. Given the equivalent antigen load after i.v. versus s.c. inoculation of an identical number of C1498.SIY cells, it was conceivable that the i.v.-disseminated leukemia cells not only failed to prime a specific T cell response, but might have actively induced peripheral tolerance. To determine whether this was the case, mice received i.v. C1498.SIY cell inoculation on day –6, followed by s.c. C1498.SIY cell challenge on day 0 (a dual-challenge approach referred to herein as i.v./s.c.). In fact, strikingly diminished functional SIY-specific T cell responses were observed in the spleens and tumor-draining LNs (DLNs) of mice subjected to i.v./s.c. administration (Figure 2, A and B). Similar findings were observed in parallel experiments in which control C1498 cells were used (Figure 2C), which suggests that T cell dysfunction induced by i.v. C1498 cells was not dependent upon their expression of the SIY antigen. Thus, hematogenous dissemination of AML cells actively promoted the induction of T cell dysfunction in C57BL/6 mice.

To ensure that the T cell tolerance to i.v.-disseminated leukemia was not an artifact of an individual cell line, parallel experiments were performed using murine FBL cells that naturally express the retroviral Gag protein. C57BL/6 mice received i.v., s.c., or i.v./s.c. inoculation of FBL cells as above, and Gag-specific CD8+ T cell responses were analyzed by IFN-γ ELISPOT after ex vivo restimulation with Gag peptide. Strikingly diminished functional Gag-specific endogenous CD8+ T cell responses were again observed in mice that received i.v./s.c. inoculation (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI63980DS1). These results argue that induction of peripheral T cell tolerance is a common mechanism of immune evasion in hosts with disseminated AML.

To determine whether the ability of i.v. C1498 cell inoculation to induce peripheral tolerance was dose dependent, a range of cell numbers was introduced i.v. Indeed, increasing numbers of i.v. C1498.SIY cells led to progressively diminished functional SIY-specific T cell responses after subsequent s.c. inoculation with 10⁶ C1498.SIY cells 6 days later (Figure 2D). To determine whether the induction of peripheral tolerance was unique to the i.v. setting, groups of C57BL/6 mice were inoculated i.v. or s.c. with C1498.SIY cells on the left flank on day –6; on day 0, both groups received a second inoculation of s.c. C1498.SIY cells on the right flank. Whereas the i.v./s.c. recipients failed to generate a functional SIY-specific T cell response, in sharp contrast, enhanced SIY-specific T cell responses were seen in spleens of s.c./s.c. recipients (Figure 2E). This suggests that the initial s.c. C1498.SIY cell inoculation on day –6 actually promoted antigen-specific T cell priming, similar to what might be expected with a tumor cell–based vaccine. To determine whether a functional antigen-specific T cell response after s.c. C1498.SIY cell inoculation could be inhibited by subsequent i.v. C1498.SIY cell inoculation, groups of C57BL/6 mice were challenged with s.c. C1498.SIY cells on day –6, and some received subsequent i.v. C1498.SIY cell inoculation on day 0. Functional SIY-specific T cell responses were analyzed in the spleens of these mice 6 days later, which demonstrated that antigen-specific T cell responses in mice receiving s.c./i.v. C1498.SIY cell inoculation were similar to those in mice receiving s.c. C1498.SIY cell inoculation alone (Supplemental Figure 2). This result suggested that once antigen-specific CD8+ T cells were functionally primed
after s.c. C1498.SIY cell challenge, they were no longer sensitive to tolerization with a subsequent i.v. C1498.SIY cell challenge. It was important to exclude the possibility that global immune suppression as a result of advanced tumor burden was responsible for the defective antigen-specific T cell responses seen in mice after i.v. C1498.SIY cell inoculation. To address this, C57BL/6 mice were challenged with live or irradiated (150 Gy) C1498.SIY cells i.v. on day –6, followed by s.c. C1498.SIY cell challenge on day 0. This dose of
radiation was found to be nearly 100% lethal to C1498.SIY cells, as assessed by a trypan blue exclusion assay (data not shown). Diminished SIY-specific T cell responses against s.c. C1498.SIY tumors were observed whether live or irradiated C1498.SIY cells were previously introduced (Figure 2F), which argues that systemic immune suppression from a rapidly growing tumor was not the cause of peripheral tolerance induced after i.v. C1498.SIY cell inoculation.

T cell dysfunction in mice bearing i.v. C1498.SIY cells occurs in an antigen-specific manner. To determine whether the T cell dysfunction induced by i.v. C1498.SIY cells was specific to the antigens expressed on the tumor cells, 2 experiments were performed. First, groups of C57BL/6 mice were challenged i.v. with either C1498.SIY cells or C1498.SIY cells on day –6. On day 0, these mice received s.c. C1498.SIY cells or i.v. C1498.SIY cells, and IFN-γ ELISPOT was performed. *$p < 0.05$. Data are representative of 3 independent experiments with 3 mice/group. (A) 6 days after inoculation of control C1498 cells i.v., s.c., or i.v./s.c., LN cells were restimulated with media or irradiated C1498 cells in an IFN-γ ELISPOT assay. *$p < 0.05$. (D) Indicated numbers of i.v. C1498.SIY cells were introduced on day –6, followed by 10^6 s.c. C1498.SIY cells on day 0. On day 6, IFN-γ ELISPOT was performed. *$p < 0.05$ versus all other groups. (E) Mice received C1498.SIY cells as in A. A fourth group received s.c. C1498.SIY cells in one flank on day –6, and the opposite flank on day 0 (s.c./s.c.). IFN-γ ELISPOT was performed on day 6. *$p < 0.05$. (F) Live or irradiated C1498.SIY cells were inoculated i.v., s.c., or i.v./s.c., and IFN-γ ELISPOT was performed. *$p < 0.05$. (C–F) Data are representative of 2 experiments with 3 mice/group.
not shown). We speculated that a state of “shared tolerance” to unknown antigens on C1498 cells might explain this result. Thus, we next used a different cancer cell line expressing a different model antigen to determine whether T cell tolerance in i.v.-challenged mice was antigen specific. Groups of C57BL/6 mice were challenged with i.v. C1498.SIY cells on day –6 and received a subsequent s.c. challenge on day 0 with C1498.SIY cells or B16.OVA cells (B16 melanoma cells engineered to express the full-length chicken OVA protein). On day 6, spleen cells were restimulated ex vivo with either the SIY peptide or a Kβ-restricted OVA-derived peptide (SIINFEKL) in an IFN-γ ELISPOT assay. SIY-specific CD8+ T细胞 responses were reduced before, whereas OVA-specific T cell responses remained intact (Figure 3A). This result suggests that T cell dysfunction in mice inoculated with i.v. C1498.SIY cells occurred in an antigen-specific manner.

**Figure 3**

T cell dysfunction in mice after i.v. C1498.SIY cell inoculation is antigen specific, and is not regulated by Tregs or MDSCs. (A) C57BL/6 mice received 10^6 C1498.SIY or B16.OVA cells s.c. only. Additional cohorts of mice received 10^6 C1498.SIY cells i.v. on day –6, followed by either C1498.SIY or B16.OVA cells s.c. on day 0. On day 6, spleen cells were restimulated with SIY or OVA peptide in an IFN-γ ELISPOT assay. *P < 0.05. (B) FoxP3-DTR mice received C1498.SIY cells s.c. or i.v./s.c. and were treated with diphtheria toxin (DT; 1 μg in 0.1 ml per mouse) or PBS as follows: s.c. C1498.SIY cell–challenged mice, days –2, –1, 0, 2, and 5; i.v./s.c. C1498.SIY cell–challenged mice, days –6, –7, –4, –1, 2, and 5. On day 6, an IFN-γ ELISPOT assay was performed. (C) C57BL/6 mice received s.c. or i.v./s.c. C1498.SIY cells and received either the anti–Ly-6G Ab 1A8 or isotype control Ab (300 μg i.p. on days 0 and 3 for s.c. challenge, and on days –6, –3, 0, and 3 for i.v./s.c. challenge). On day 6, spleen cells were restimulated with media or SIY peptide in an IFN-γ ELISPOT assay. (A–C) Data are representative of 2 experiments with 3 mice/group.
Figure 4
SIY-specific 2C T cells undergo abortive peripheral tolerance in mice with i.v. C1498.SIY. CFSE-labeled 2C T cells (4 × 10⁶) were adoptively transferred into C57BL/6 mice, followed 1 day later by inoculation with i.v. or s.c. C1498.SIY cells. (A) On day 7, 2C T cells were enumerated. *P < 0.05, i.v. versus s.c. Data are representative of 4 experiments with 3–5 mice/group. (B) Representative FACS plots from mice in A. Gated areas represent percent 2C T cells among the entire CD8⁺ T cell population. (C) Mean percent 2C T cells from mice in A. *P < 0.05, i.v. versus s.c. (D) CFSE dilution of 2C T cells from mice in A. (E) Mice received 2C T cells and C1498.SIY challenge as in A. On day 7, spleen and LN cells were restimulated with media or SIY peptide. Production of IFN-γ by 2C T cells was analyzed. Numbers represent percent IFN-γ⁺ 2C T cells. (F) Numbers of IFN-γ-producing 2C T cells after i.v. or s.c. C1498.SIY cell challenge. *P = 0.10, **P < 0.05, i.v. versus s.c. (E and F) Data are representative of 3 experiments with 3 mice/group.
**Discussion**

The mechanisms that regulate T cell activation versus tolerance in the setting of hematological malignancies such as AML have not been well clarified. A more thorough understanding of these pathways is important in order to ultimately develop strategies to enhance leukemia-specific immunity in patients. Our results revealed a striking contrast between the nature of antigen-specific T cell responses generated against malignant cells introduced at a local s.c. site versus those inoculated systemically. In the former scenario, robust antigen-specific CD8+ T cell responses were induced, while in the latter, a profound state of antigen-specific T cell tolerance was generated. This peripheral tolerance appeared to result from a combination of T cell deletion and T cell–intrinsic dysfunction. An overarching implication of the present results

---

**Endogenous antigen-specific T cell responses are restored, and mouse survival is prolonged, after administration of agonistic anti-CD40 Ab.** In other models of induction of peripheral tolerance, for example through the use of costimulatory ligand blockade (26), T cell deletion and anergy appear to operate in concert to induce and maintain the tolerant state. It seemed plausible that a similar process might be occurring with i.v. dissemination of tumor, if antigen cross-presentation was occurring by host DCs that were not activated or matured. Although CD11c+ cells from spleens and LNs of mice after i.v. versus s.c. C1498.SIY cell inoculation did not differ significantly in their expression of MHC class I or classical costimulatory molecules (data not shown), we nevertheless hypothesized that there might be a qualitative defect in the ability of DCs from i.v.-challenged mice to functionally prime leukemia antigen-specific T cells. As CD40 ligation has previously been shown to activate DCs in vivo (21, 22, 27), we investigated whether administration of an agonistic anti-CD40 Ab in mice inoculated with i.v. C1498.SIY cells would restore T cell activation and persistence, improving leukemia control and, hence, mouse survival. In the 2C T cell adoptive transfer system, anti-CD40 treatment of mice led to a markedly enhanced ability of 2C T cells to proliferate and accumulate in hosts harboring i.v. C1498.SIY cells (Figure 6A), which suggests that deletion of antigen-specific T cells was prevented. CD40 ligation also led to markedly enhanced production of IFN-γ and TNF-α by antigen-specific 2C T cells (Figure 6B).

We then examined the effect of anti-CD40 mAb on the endogenous T cell response to i.v. C1498.SIY cells. Anti-CD40 mAb induced markedly higher frequencies and absolute numbers of endogenous SIY-specific CD8+ T cells in C57BL/6 mice with i.v. C1498.SIY cell challenge compared with those seen in isotype control Ab–treated mice (Figure 6C and data not shown). In contrast, anti-CD40 treatment had no significant effect on the frequency of SIY-reactive CD8+ T cells in mice after s.c. C1498.SIY cell challenge (Figure 6C). Similarly, functional SIY-specific T cell responses were strikingly enhanced in mice after i.v. C1498.SIY cell inoculation and anti-CD40 treatment. Again, anti-CD40 treatment did not significantly augment the already robust functional SIY-specific T cell responses that occurred naturally after s.c. C1498.SIY cell challenge (Figure 6D). Furthermore, anti-CD40 treatment prevented the T cell tolerance induced by i.v. C1498.SIY cell inoculation in i.v./s.c. C1498.SIY cell dual-challenged mice, as measured by functional SIY-specific T cell responses (Figure 6E).

In keeping with augmented SIY-specific T cell responses, significantly prolonged survival — and, in some cases, disease cure — was observed in mice after i.v. C1498.SIY cell inoculation and treatment with anti-CD40 versus isotype control Ab (Figure 6F), even when i.v. C1498.SIY cells were established 8 days prior to initiation of anti-CD40 treatment (Figure 6G). To determine whether anti-CD40 treatment could prolong survival in a second transplantable AML model, groups of C57BL/6 mice received i.v. challenge with FBL cells. Because of the aggressive nature of FBL (death within 2.5 weeks of i.v. challenge with 10⁶ FBL cells), C57BL/6 mice were inoculated with i.v. FBL cells and treated with anti-CD40 or isotype control Ab 5 days later. Similar to what was observed in the C1498 model, anti-CD40 treatment of C57BL/6 mice harboring i.v. FBL cells led to an impressive prolongation of survival (Figure 6H). Collectively, these results argue that the T cell–tolerant state generated in mice with i.v. C1498.SIY cells is likely regulated by tolerogenic host APCs, in a way that can be prevented and, more importantly, reversed in vivo after treatment with an agonistic anti-CD40 Ab.
Figure 5

Tg expression of Bcl-XL in 2C T cells rescues them from deletion in hosts with i.v. C1498.SIY cells. (A) CFSE-labeled 2C or 2C\textsuperscript{BCL-XL} T cells were transferred into C57BL/6 mice. On day 1, mice received i.v. or s.c. C1498.SIY cells. On day 7, CFSE dilution of splenic 2C and 2C\textsuperscript{BCL-XL} T cells was analyzed. Representative CFSE dilution profiles are shown. (B) Absolute numbers of 2C T cells in spleens of mice in A. *P < 0.05. (C) 2C or 2C\textsuperscript{BCL-XL} T cells were transferred into mice and subsequently challenged with i.v. or s.c. C1498.SIY cells as in A. On day 7, spleen cells were restimulated with media or SIY peptide, and production of IFN-γ and TNF-α was analyzed. Numbers represent percent 2C T cells producing the indicated cytokines. (B and C) Data are representative of 2 experiments with 3 mice/group. (D) Percent 2C and 2C\textsuperscript{BCL-XL} T cells in spleens and livers of mice 24 days after i.v. C1498.SIY cell challenge. Representative plots are shown. Gated areas represent percent 2C or 2C\textsuperscript{BCL-XL} T cells among the entire CD8\textsuperscript{T} cell population. Mean percent 2C and 2C\textsuperscript{BCL-XL} T cells in groups of 3 mice is also shown. *P < 0.05, 2C\textsuperscript{BCL-XL} versus 2C. Data are representative of 2 experiments.
Figure 6

Agonistic CD40 ligation prevents T cell deletion, priming large numbers of activated T cells, in mice harboring C1498.SIY cells i.v. (A) CFSE dilution of 2C T cells 7 days after transfer into C57BL/6 mice challenged with i.v. C1498.SIY cells and treated with anti-CD40 or isotype control Ab (IC). (B) Splenocytes from mice in A were restimulated with media or SIY peptide, and IFN-γ and TNF-α production by 2C T cells was assessed. Numbers represent percent cytokine-producing 2C T cells. (C) C57BL/6 mice received i.v. or s.c. C1498.SIY cells and were treated with anti-CD40 or isotype control Ab. On day 6, percent SIY-reactive splenic CD8+ T cells was analyzed. A negative control OVA tetramer was also used. *P < 0.05 versus all other groups. (D) IFN-γ ELISPOT analysis of splenocytes from mice in C. *P < 0.05 versus control Ab. (E) C57BL/6 mice received C1498.SIY cells i.v. on day –6 and were treated with anti-CD40 or isotype control Ab on days –6 and –3. On day 0, these mice were challenged with C1498.SIY cells s.c. Control mice received C1498.SIY cells i.v. or s.c. on day 0 only. IFN-γ ELISPOT analysis was performed on day 6. (F) C57BL/6 mice received C1498.SIY cells i.v. On days 0, 2, and 4, anti-CD40 or isotype control Ab was administered, and survival was assessed. *P = 0.002 versus control Ab. (G) C57BL/6 mice received i.v. C1498.SIY cells on day 0. On days 8, 10, 12, 17, 22, and 27, anti-CD40 or isotype control Ab was administered, and survival was assessed. *P = 0.05 versus control Ab. (H) C57BL/6 mice received FBL cells i.v. on day 0. On days 5, 7, 9, 13, and 18, anti-CD40 or isotype control Ab was administered, and survival was assessed. *P < 0.05 versus control Ab. Data are representative of 2 independent experiments with 3 (A–E) or 5 (F–H) mice/group.
is that leukemia cells may promote immune evasion indirectly through host APCs that cross-present leukemia-derived antigens in a context unfavorable for T cell activation.

The observation that T cell deletion played an important role in the promotion of immune dysfunction generated by AML cells has not been described in other experimental tumor models. Ohlen and colleagues used FBL in order to study the CD8+ T cell response to an immunodominant epitope (Gag) expressed by FBL cells, in a setting in which the Gag protein was also transgenically expressed in the liver and, to a lesser extent, the thymus (Alb-Gag mice) (28). In this model, tolerant Gag-specific CD8+ T cells failed to proliferate or produce IL-2 upon restimulation and demonstrated abnormal calcium flux and Ras/MAPK signaling, a picture most consistent with T cell anergy, which was later demonstrated to be reversible after IL-15 administration (15, 28). However, Tg expression of the target antigen in the liver likely skewed the peripheral tolerance mechanism toward anergy as the dominant outcome; the tolerance in our experiments resulted from antigen derived only from the leukemia cells. Staveley-O’Carroll et al. developed a model in which A20 lymphoma cells were engineered to express a model MHC class II–restricted antigen derived from the influenza virus (HA), and showed that naive HA-specific CD4+ TCR Tg T cells became anergic after their adoptive transfer into hosts along with systemic challenge with A20-HA cells (12). The induction of anergy in this model was not generated by the A20 cells themselves, but rather depended upon host APCs, as it did not occur in bone marrow chimeric mice in which hematopoietic cells were incapable of cross-presenting the HA antigen to CD4+ T cells (13). Similarly, in the current model, it is unlikely that C1498 cells were acting as suppressive APCs after their i.v. inoculation into mice, as they expressed similar levels of MHC class I molecules and failed to upregulate costimulatory molecules, such as B7-1, B7-2, or CD40 when analyzed directly ex vivo from hosts into which they had been inoculated i.v. or s.c. (data not shown). These observations support our findings suggesting a role for host APCs in the induction of tolerance in hosts with hematological malignancies. In contrast to prior models, T cell tolerance in hosts with systemic dissemination of C1498 leukemia involved a combined effect of deletion and T cell dysfunction to explain peripheral tolerance, which could be prevented with CD40 ligation on host APCs.

It is interesting to speculate that T cell deletion and anergy might represent a continuum of dysfunctional T cell activation. Whether a T cell becomes functionally activated, is anergized, or is deleted likely depends upon the affinity of the TCR for its antigen and the context in which the antigen is encountered. For example, Sherman et al. have demonstrated that TCR Tg CD8+ T cells were instructed to undergo an abortive proliferative response and to become tolerant upon transfer into mice in which the cognate antigen was cross-presented by quiescent APCs in a noninflamed LN environment (29, 30). By administering the antigenic peptide systemically into mice, it was determined that higher doses of antigen led to T cell anergy, while repeated low doses of antigen promoted T cell deletion (31). While T cell deletion appears to be a major mechanism of T cell tolerance in the C1498 model, it is likely that the small number of antigen-specific T cells that escaped deletion may have been rendered anergic. 2C T cells analyzed from mice with i.v. C1498.SIY produced significantly lower levels of IFN-γ and TNF-α compared with 2C T cells from mice with s.c. C1498.SIY, consistent with this notion.

Recent data from transplantable solid tumor models have indicated that innate signals, such as type I IFNs (18, 32), ATP (33), uric acid (34), tumor cell–derived DNA, and HMGB-1 (17), can be produced or released locally in the solid tumor microenvironment and lead to an adaptive T cell response against tumor antigens. However, because leukemia cells progressing in the circulation may not be capable of inducing the level of local inflammation necessary for productive T cell priming, it is possible that the APCs that cross-present leukemia-specific antigens do so in a context not favorable to T cell activation, and rather, they induce T cell tolerance.

An area of ongoing research in our laboratory is to define more precisely which APC populations mediate antigen-specific T cell tolerance to leukemia. It is conceivable that a specific APC subpopulation (35, 36), or that an immature activation state of any host APC, is responsible for promoting T cell tolerance. Future characterization of this mechanism may allow further refinements in strategies to prevent and/or reverse leukemia-induced tolerance.

Our results have 2 important implications for clinical translation of immunotherapeutic approaches in AML. First, the ideal scenario for promoting a leukemia-specific T cell response will likely be in the minimal residual disease setting, for example, after remission-induction therapy, so that the systemic delivery of leukemia-derived antigens that promote tolerance will be minimized and immune reconstitution of the host will have occurred. Second, our results suggest that agonistic CD40 Abs should be explored in patients with AML, a strategy that has become feasible given the availability of clinical-grade anti-CD40 Abs being explored for cancer immunotherapy (37, 38).

**Methods**

**Mice and tumor cell lines.** C57BL/6 (H-2b) mice, aged 6–12 weeks, were purchased from either Jackson Laboratories or Taconic laboratories. Thy1.1+ congenic C57BL/6 mice were purchased from Jackson Laboratories and bred in our facility. 2C TCR-Tg mice on the C57BL/6 background (39) were bred in our animal facility. B6.XL Tg mice, in which BCL-XL expression is knocked out, were obtained from Jackson Laboratories or Taconic laboratories. Thy1.1+ congenic C57BL/6 mice were purchased from Jackson Laboratories and bred in our facility. 2C TCR-Tg mice on the C57BL/6 background (39) were bred in our animal facility. B6.XL Tg mice, in which BCL-XL expression is knocked out, were obtained from Jackson Laboratories or Taconic laboratories. Thy1.1+ congenic C57BL/6 mice were purchased from Jackson Laboratories and bred in our facility. 2C TCR-Tg mice on the C57BL/6 background (39) were bred in our animal facility. B6.XL Tg mice, in which BCL-XL expression is knocked out, were obtained from Jackson Laboratories or Taconic laboratories.

**C57BL/6** dark and light homozygous mice were bred in our animal facility. FoxP3-DTR animals (41) were obtained from A. Rudensky. Animals were maintained in a specific pathogen-free environment. The C1498 murine AML cell line (19) was purchased from ATCC. C1498 cells were cultured in complete DMEM supplemented with 10% fetal calf serum. C1498.GFP cells were engineered by retroviral transduction using the pLEGFP plasmid. C1498.SIY cells were engineered by retroviral transduction using the pLEGFP plasmid expressing cDNA for the SIY model peptide antigen in frame with eGFP. Cell surface expression of the SIY peptide is Kα restricted, and thus can be recognized by a small fraction of endogenous C57BL/6 CD8+ T cells and is also specifically recognized by the 2C TCR Tg CD8+ T cells. B16.OVA cells, expressing the full-length chicken OVA protein, were a gift from Y.-X. Fu (University of Chicago). The FBL cell line is an MHC class I, II, and class II human AML cell line expressing the FMuLV gag peptide (CCLCLTVFL), which is presented in the context of Kα.

**Tumor cell inoculation.** C1498, C1498.GFP, C1498.SIY, and B16.OVA cells were washed 3 times with PBS to remove FCS and resuspended in PBS at a concentration of 106–107 cells/ml. For i.v. injection, a volume of 0.1 ml (105–106 tumor cells) was injected into the lateral tail vein of each mouse. For s.c. challenge, a volume of 0.1 ml (105 tumor cells) was injected under the skin of the right lower lateral abdominal wall. For experiments with FBL, 105 cells were inoculated i.v. or s.c.
IFN-γ ELISPOT. ELISPOT was conducted with the BD Bioscience mouse IFN-γ ELISPOT kit according to the provided protocol. Briefly, ELISPOT plates were coated with anti-mouse IFN-γ Ab and stored overnight at 4°C. Plates were then washed and blocked with DMEM supplemented with 10% FCS for 2 hours at room temperature. Splenocytes or LN cells (DLNs for s.c. inoculation; pooled inguinal and axillary LNs for i.v. inoculation) from individual tumor-challenged mice were harvested at various time points and plated in triplicate at between 5 × 10^4 and 1 × 10^5 cells/well. Unless otherwise indicated, stimulation was performed with irradiated (150 Gy) C1498 cells (5 × 10^4 cells/well) or SIY peptide (80 nM). Stimulation with media alone or with PMA (50 ng/ml) and ionomycin (500 nM) served as negative and positive controls, respectively. Plates were stored at 37°C in an 8% CO2 incubator overnight, washed, and coated with streptavidin-PE or streptavidin-allophycocyanin. FACS analysis was performed on a FACScanto cytometer using BD FACSDiva software. Data analysis was performed using FlowJo software (Tree Star Inc.).

Intracellular cytokine staining. Spleens and LN cells were harvested from C57BL/6 mice 6 days after 2C T cell transfer and C1498.SIY cell challenge as described above. 10^6 spleen or LN cells from individual mice were plated in flat-bottom 96-well tissue culture plates and stimulated with medium alone, or in medium supplemented with SIY peptide (500 nM), or PMA and ionomycin at 37°C for 4 hours in the presence of brefeldin-A (1 μg/ml). Subsequently, cells were recollected, stained with anti-Thy1.2–allophycocyanin or anti-1B2–biotin Ab and streptavidin-PE or PerCP-Cy5.5 in combination with an anti-CD8–allophycocyanin Ab. After washing, wells were fixed (Cytofix; BD Bioscience) for 10 minutes at room temperature; permeabilized; stained with anti-IFN-γ-PE-Cy7 and/or anti-TNF-α-PE Abs; and analyzed for cytokine production by flow cytometry after gating on 2C T cells (Thy1.2 or 1B2). In vivo administration of agonistic anti-CD40 Ab. Groups of C57BL/6 mice were challenged with 10^6 C1498.SIY cells i.v. or s.c. on day 0, or remained tumor free. On days 0, 2, and 4, mice received i.p. injection of agonistic anti-CD40 Ab (FGK45; 100 μg) or isotype control Ab. On day 6, spleen and LN cells from tumor-challenged and naive mice treated with anti-CD40 or isotype control Ab were isolated, analyzed by flow cytometry after SIY or OVA pentamer staining (as above), and also restimulated using IFN-γ ELISPOT assay (as above).

Statistics. A 2-tailed Student’s t test was used to analyze differences in numbers of IFN-γ spot-forming cells and SIY/Kp pentamer–reactive CD8+ cells in individual mice assigned to various treatment groups, and also to compare numbers of 2C T cells present in mice challenged with i.v. versus s.c. C1498.SIY cells. A P value of 0.05 or less between groups was considered statistically significant. The log-rank test was used to compare survival differences between groups of tumor-challenged mice. Data are presented as mean ± SD in all experiments performed.

Study approval. Animals were used according to protocols approved by the IACUC of University of Chicago according to NIH guidelines for animal use.

Acknowledgments
This work was supported by K23 CA133196 and R01 CA16670 (to J. Kline).

Received for publication March 22, 2012, and accepted in revised form February 21, 2013.

Address correspondence to: Justin Kline, Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Ave., MC 2115, Chicago, Illinois 60637, USA. Phone: 773.702.5550; Fax: 773.702.3163; E-mail: jkline@medicine.bsd.uchicago.edu.

14. Sotomayor EM. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but...